Correct, Filbert. One announcement said capital mgt (dividends, SBB) are limited to 30% of EBITDA (or NPAT?) until next end of Feb or March. Even so, I doubt DNA has spent anywhere near that limit on SBB yet.
Keep in mind that SBBs don't boost the SP, at least not often. The ATO/ASIC rules even limit SBBs above a moving average price, supposedly to limit any boost effect. Instead, SBBs mainly have the longer term (1 year+) benefit of increasing each shareholder's slice of the asset and earnings pie. SBBs are also increasingly necessary to thwart systemic short selling. Fortunately, DNA short sales have been fairly tame recently, assuming ATO/ASIC numbers are accurate.
DNA Price at posting:
32.0¢ Sentiment: Hold Disclosure: Held
